References
- 1. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system. J Clin Oncol 2004; 14: 2865-72.
- 2. Smedby KE, Brandt L, Backlund ML, Blomqvist P. Brain metastases admissions in Sweden between 1987 and 2006. Br J Cancer 2009; 11: 1919-24.
- 3. Fidler IJ, Yano S, Zhang RD, Fujimaki T, Bucana CD. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol 2002; 1: 53-7.
- 4. Khuntia D, Brown P, Li J, Mehta MP. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 2006; 8: 1295-304.
- 5. Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neuro-Oncol 1999; 3: 275-81.
- 6. Li J, Bentzen SM, Li JL, Renschler M, Mehta MP. Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis. Int J Radiat Oncol Biol Physics 2008; 1: 64-70.
- 7. Lekic M, Kovac V, Triller N, Knez L, Sadikov A, Cufer T. Outcome of small cell lung cancer (SCLC) patients with brain metastases in a routine clinical setting. Radiol Oncol 2012; 1: 54-9.
- 8. Nussbaum ES, Djalilian HR, Cho KH, Hall WA. Brain metastases - Histology, multiplicity, surgery, and survival. Cancer 1996; 8: 1781-8.
- 9. Li J, Bentzen SM, Renschler M, Mehta MP. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol 2007; 10: 1260-6.
- 10. Agerholm-Larsen B, Iversen HK, Ibsen P, Moller JM, Mahmood F, Jensen KS, et al. Preclinical validation of electrochemotherapy as an effective treatment for brain tumors. Cancer Res 2011; 11: 3753-62.
- 11. Bhangoo SS, Linskey ME, Kalkanis SN. Evidence-based guidelines for the management of brain metastases. Neurosurg Clin N Am 2011; 1: 97-+.
- 12. Jenkinson MD, Haylock B, Shenoy A, Husband D, Javadpour M. Management of cerebral metastasis: Evidence-based approach for surgery, stereotactic radiosurgery and radiotherapy. Eur J Cancer 2011; 5: 649-55.
- 13. Stanic K, Kovac V. Prophylactic cranial irradiation in patients with small-cell lung cancer: the experience at the Institute of Oncology Ljubljana. Radiol Oncol 2010; 3: 180-6.
- 14. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009; 11: 1037-44.
- 15. Videtic GM, Gaspar LE, Aref AM, Germano IM, Goldsmith BJ, Imperato JP, et al. American College of Radiology appropriateness criteria on multiple brain metastases. Int J Radiat Oncol Biol Phys 2009; 4: 961-5.
- 16. Kalkanis SN, Kondziolka D, Gaspar LE, Burri SH, Asher AL, Cobbs CS, et al. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncol 2010; 1: 33-43.
- 17. Patchell RA, Regine WF. The rationale for adjuvant whole brain radiation therapy with radiosurgery in the treatment of single brain metastases. Technol Cancer Res Treatm 2003; 2: 111-5.
- 18. Bahl A, Kumar M, Sharma DN, Basu KSJ, Jaura MS, Rath GK, et al. Reirradiation for progressive brain metastases. J Cancer Res Ther 2009; 3: 161-4.
- 19. Hazuka MB, Kinzie JJ. Brain metastases - results and effects of re-irradiation. Int J Radiat Oncol Biol Phys 1988; 2: 433-7.
- 20. Addeo R, Caraglia M, Faiola V, Capasso E, Vincenzi B, Montella L, et al. Concomitant treatment of brain metastasis with Whole Brain Radiotherapy [WBRT] and Temozolomide [TMZ] is active and improves Quality of Life. Bmc Cancer 2007.
- 21. Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study. J Clin Oncol 2004; 11: 2101-7.
- 22. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 2005; 10: 987-96.
- 23. Verger E, Miguel G, Yaya R, Vinolas N, Villa S, Pujol T, et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: A phase II randomized trial. Int J Radiat Oncol Biol Phys 2005; 1: 185-91.
- 24. Mehta MP, Paleologos NA, Mikkelsen T, Robinson PD, Ammirati M, Andrews DW, et al. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncol 2010; 1: 71-83.
- 25. Antonadou D, Paraskevaidis M, Sarris G, Coliarakis N, Economou I, Karageorgis P, et al. Phase II Randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002; 17: 3644-50.
- 26. Rivera E, Meyers C, Groves M, Valero V, Francis D, Arun B, et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 2006; 6: 1348-54.
- 27. Newton HB, Slivka MA, Volpi C, Bourekas EC, Christoforidis GA, Baujan MA, et al. Intra-arterial carboplatin and intravenous etoposide for the treatment of metastatic brain tumors. J Neuro-Oncol 2003; 1: 35-44.
- 28. Kiewe P, Thiel E, Reinwald M, Korfel A. Topotecan and ifosfamide systemic chemotherapy for CNS involvement of solid tumors. J Neuro-Oncol 2011; 3: 629-34.
- 29. Addeo R, Caraglia M. The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer? Expert Review Anticancer Ther 2011; 2: 139-42.
- 30. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008; 12: 1993-9.
- 31. Lin NU, Dieras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009; 4: 1452-9.
- 32. Gore ME, Hariharan S, Porta C, Bracarda S, Hawkins R, Bjarnason GA, et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 2011; 3: 501-9.
- 33. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008; 11: 1810-16.
- 34. Novello S, Camps C, Grossi F, Mazieres J, Abrey L, Vernejoux JM, et al. Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases. J Thorac Oncol 2011; 7: 1260-6.
- 35. Franceschi E, Brandes AA. Brain metastases from non-small-cell lung cancer: is there room for improvement? Exp Rev Anticancer Ther 2012; 4: 421-3.
- 36. Porta R, Sanchez-Torres JM, Paz-Ares L, Massuti B, Reguart N, Mayo C, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J 2011; 3: 624-31.
- 37. Labidi SI, Bachelot T, Ray-Coquard I, Mosbah K, Treilleux I, Fayette J, et al. Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: A case series. Clin Breast Cancer 2009; 2: 118-21.
- 38. Gehl J, Sorensen TH, Nielsen K, Raskmark P, Nielsen SL, Skovsgaard T, et al. In vivo electroporation of skeletal muscle: threshold, efficacy and relation to electric field distribution. Biochim Biophys Acta 1999; 2-3: 233-40.
- 39. Tounekti O, Kenani A, Foray N, Orlowski S, Mir LM. The ratio of single- to double-strand DNA breaks and their absolute values determine cell death pathway. Br J Cancer 2001; 9: 1272-79.
- 40. Orlowski S, Belehradek J, Paoletti C, Mir LM. Transient electropermeabilization of cells in culture - Increase of the cyto-toxicity of anticancer drugs. Biochem Pharmacol 1988; 24: 4727-33.
- 41. Gothelf A, Mir LM, Gehl J. Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev 2003; 5: 371-87.
- 42. Mir LM, Gehl J, Sersa G, Collins CG, Garbay JR, Billard V, et al. Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the Cliniporator (TM) by means of invasive or non-invasive electrodes. EJC Suppl 2006; 11: 14-25.
- 43. Gehl J, Skovsgaard T, Mir LM. Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugs. Anti-Cancer Drug 1998; 4: 319-25.
- 44. Jaroszeski MJ, Dang V, Pottinger C, Hickey J, Gilbert R, Heller R. Toxicity of anticancer agents mediated by electroporation in vitro. Anti-Cancer Drug 2000; 3: 201-8.
- 45. Matthiessen LW, Chalmers RL, Sainsbury DCG, Veeramani S, Kessell G, Humphreys AC, et al. Management of cutaneous metastases using electrochemotherapy. Acta Oncol 2011; 5: 621-9.
- 46. Heller R, Jaroszeski MJ, Reintgen DS, Puleo CA, DeConti RC, Gilbert RA, et al. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer 1998; 1: 148-57.
- 47. Marty M, Sersa G, Garbay JR, Gehl J, Collins CG, Snoj M, et al. Electrochemotherapy - An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. EJC Suppl 2006; 11: 3-13.
- 48. Belehradek M, Domenge C, Luboinski B, Orlowski S, Belehradek J, Mir LM. Electrochemotherapy, a new antitumor treatment - 1st clinical phase-I-Ii trial. Cancer 1993; 12: 3694-700.
- 49. Gehl J. Investigational treatment of cancer using electrochemotherapy, electrochemoimmunotherapy and electro-gene transfer. Ugeskr Laeger 2005; 34: 3156-9.
- 50. Gehl J, Skovsgaard T, Mir LM. Vascular reactions to in vivo electroporation: characterization and consequences for drug and gene delivery. Biochim Biophys Acta 2002; 1-3: 51-8.
- 51. Sersa G, Jarm T, Kotnik T, Coer A, Podkrajsek M, Sentjurc M, et al. Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma. Brit J Cancer 2008; 2: 388-98.
- 52. Soden D, Morrissey A, Collins C, Piggott J, Larkin J, Norman A, et al. Electrotherapy of tumour cells using flexible electrode arrays. Sensor Actual B-Chem 2004; 1-2: 219-24.
- 53. Mahmood F, Gehl J. Optimizing clinical performance and geometrical robustness of a new electrode device for intracranial tumor electroporation. Bioelectrochemistry 2011; 1: 10-6.
- 54. Edhemovic I, Gadzijev EM, Brecelj E, Miklavcic D, Kos B, Zupanic A, et al. Electrochemotherapy: a new technological approach in treatment of metastases in the liver. Technol Cancer Res Treatm 2011; 5: 475-85.
- 55. Salford LG, Persson BR, Brun A, Ceberg CP, Kongstad PC, Mir LM. A new brain tumour therapy combining bleomycin with in vivo electropermeabilization. Biochem Biophys Res Commun 1993; 2: 938-43.
- 56. Agerholm-Larsen B, Iversen HK, Moller J, Ibsen P, Jensen KS, Linnert M, et al. Effect of electrochemotherapy with IV bleomycin on complete response in a preclinical brain tumor study. J Clin Oncol 2012, 30: abstr 2069.
- 57. Linnert M, Gehl J. Bleomycin treatment of brain tumors: an evaluation. Anti-Cancer Drugs 2009; 3: 157-64.
- 58. Osanto S, Bukman A, Vanhoek F, Sterk PJ, Delaat JAPM, Hermans J. Longterm effects of chemotherapy in patients with testicular cancer. J Clin Oncol 1992; 4: 574-9.
- 59. Pliarchopoulou K, Pectasides D. Late complications of chemotherapy in testicular cancer. Cancer Treatm Rev 2010; 3: 262-7.